AsymmetRx

AsymmetRx is a biotechnology company specializing in the development of novel diagnostic tools for the early detection and management of cancer, with a primary focus on prostate oncology. The company's core technology is centered on the p63 gene, a critical regulator of stem cells in epithelial tissues that serves as a definitive marker for basal cells in the prostate. AsymmetRx's p63-based diagnostic tests are widely utilized by pathologists to differentiate between benign and malignant prostate lesions, significantly improving diagnostic accuracy. Beyond prostate cancer, the company explores the application of p63 and related markers in other epithelial cancers, such as bladder and lung cancer. AsymmetRx leverages its intellectual property through strategic licensing agreements with major diagnostic and reagent providers to ensure global access to its proprietary markers.